Join our daily newsletter At The Bell to receive exclusive market insights
- Cynata Therapeutics (CYP) has received a notice of allowance from the Israel Patent Office for a patent application for its Cymerus stem cell technology
- A notice of allowance is a good indicator that the applicant’s product will be issued a patent
- Cymerus is a stem cell platform technology that can manufacture mesenchymal stem cells from a single donation
- This challenges traditional methods which posed several limitations
- Cynata expects the patent will be officially granted in mid-April this year
- Cynata is down a slight 0.42 per cent, with shares trading at $1.18 each
Cynata Therapeutics (CYP) has announced the Israel Patent Office has received a notice of allowance for a patent application covering its Cymerus technology.
The patent application is owned by the University of Wisconsin-Madison’s Wisconsin Alumni Research Foundation (WARF) and is among the intellectual property licensed from WARF to Cynata.
This allowance is significant in that the patent will extend the already strong IP protection of the Cymerus platform.
“Our broad and comprehensive patent portfolio continues to grow as we further strengthen our unique and proprietary IP around the Cymerus technology,” Cynata CEO Dr Ross Macdonald said.
Cymerus is a therapeutic stem cell platform technology that challenges other methods. It uses induced pluripotent stem cells and a precursor cell known as mesenchymoangioblast to manufacture mesenchymal stem cells (MSCs) from a single donation.
Traditional methods of manufacturing MSCs rely on isolating the cells from tissue donations. The issue with that is its dependence on donors, variability between donors, the scarcity of MSCs in adult tissue and the low proliferative capacity of adult stem cells.
“The ability of the Cymerus platform to enable manufacture of consistent, high-quality mesenchymal stem cells at scale is key to the ongoing development of off-the-shelf therapeutic stem cell products to target a range of devastating diseases worldwide,” Ross added.
Cynata expects the patent will be officially granted in mid-April this year, with an expiration date of March 12 2034.
Unfortunately, Cynata is down a slight 0.42 per cent, with shares trading at $1.18 each at 1:35 pm AEST.
